Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Minimal residual disease in hematologic disorders.

S Faderl1, R Kurzrock, Z Estrov

  • 1Department of Bioimmunotheraphy, The University of Texas M. D. Anderson Cancer Center, Houston 77030, USA.

Archives of Pathology & Laboratory Medicine
|October 28, 1999
PubMed
Summary

Detecting minimal residual disease (MRD) using sensitive lab tools like PCR assays is crucial for managing hematologic cancers. Understanding MRD helps predict relapse and improve patient outcomes in leukemia treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Next-Generation Sequencing Consensus Guidelines for Sarcoma: Progress, Gaps, and the Path Forward.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

ERBB2/HER2 landscape and prognostic impact: large-scale, real-world analysis across solid cancers.

ESMO open·2026
Same author

Interleukin-2 transcriptomic expression correlates with prolonged survival and with GNAS alterations in patients with advanced cancers.

ESMO open·2026
Same author

DART (NCI/SWOG S1609): comprehensive final results from dual checkpoint inhibition with CTLA-4 and PD-1 blockade in rare cancers.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

Response to: The pathway alteration load is a pan-cancer determinant of outcome of targeted therapies: results from the Drug Rediscovery Protocol (DRUP).

ESMO open·2025
Same author

The best management for most patients with incurable cancer is on a clinical trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2024

Area of Science:

  • Medical Oncology
  • Hematology
  • Molecular Diagnostics

Background:

  • Malignant hematologic disorders have seen dramatic treatment responses with new therapies.
  • Despite advances, disease relapse and mortality remain significant challenges.
  • Minimal residual disease (MRD) detection is increasingly important for patient management.

Purpose of the Study:

  • To summarize methods for identifying minimal residual disease (MRD).
  • To highlight the significance of MRD in hematologic malignancies.
  • To discuss MRD detection in acute leukemias and chronic myelogenous leukemia.

Main Methods:

  • Utilizing highly sensitive laboratory tools, including polymerase chain reaction (PCR) assays.
  • Employing advanced techniques for the detection, nature, quantification, and kinetics of MRD.

Related Experiment Videos

  • Reviewing established and novel methodologies for MRD identification.

    • Main Results:

    • New laboratory tools offer extraordinary sensitivity for MRD detection.
    • MRD detection provides critical insights into disease status beyond conventional methods.
    • The study emphasizes the clinical relevance of MRD in specific leukemias.

    Conclusions:

    • Sensitive MRD detection is vital for optimizing treatment strategies in hematologic cancers.
    • Understanding MRD kinetics aids in predicting and managing disease recurrence.
    • Advanced molecular techniques are transforming the approach to MRD assessment in leukemia.